Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S FREEDMAN

Showing results (71-80 of 1,272) with videos related to

Pageof 128
Sort By:
Statistics in Medicine|July 1, 1990
A stratified Wilcoxon-type test for trendD Y Pee, L S Freedman
Current Neurology and Neuroscience Reports|March 20, 2002
Immunologic therapy for relapsing-remitting multiple sclerosisH J MacLean, M S Freedman
Seminars in Nuclear Medicine|April 1, 1976
Radionuclide angiographyL R Muroff, G S Freedman
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 30, 2012
Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learnedHarold L Atkins, Mark S Freedman
Preventive Medicine|March 1, 1989
Clinical trials in diet and cancerD P Byar, L S Freedman
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 20, 2017
Five Questions Answered: A Review of Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Multiple SclerosisHarold L Atkins, Mark S Freedman
Seminars in Oncology|June 1, 1987
Cell surface markers in hematologic malignanciesA S Freedman, L M Nadler
Seminars in Hematology|April 3, 2008
Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphomaAnn S LaCasce, Arnold S Freedman
Current Opinion in Oncology|July 24, 2012
Early stage follicular lymphoma, current management and controversiesCaron A Jacobson, Arnold S Freedman
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 18, 2008
Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS studyM S Freedman, F G Forrestal
Pageof 128

Showing results (71-80 of 1,272) with videos related to

Sort By:
Pageof 128
Statistics in Medicine|July 1, 1990
A stratified Wilcoxon-type test for trendD Y Pee, L S Freedman
Current Neurology and Neuroscience Reports|March 20, 2002
Immunologic therapy for relapsing-remitting multiple sclerosisH J MacLean, M S Freedman
Seminars in Nuclear Medicine|April 1, 1976
Radionuclide angiographyL R Muroff, G S Freedman
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 30, 2012
Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learnedHarold L Atkins, Mark S Freedman
Preventive Medicine|March 1, 1989
Clinical trials in diet and cancerD P Byar, L S Freedman
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 20, 2017
Five Questions Answered: A Review of Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Multiple SclerosisHarold L Atkins, Mark S Freedman
Seminars in Oncology|June 1, 1987
Cell surface markers in hematologic malignanciesA S Freedman, L M Nadler
Seminars in Hematology|April 3, 2008
Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphomaAnn S LaCasce, Arnold S Freedman
Current Opinion in Oncology|July 24, 2012
Early stage follicular lymphoma, current management and controversiesCaron A Jacobson, Arnold S Freedman
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 18, 2008
Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS studyM S Freedman, F G Forrestal
Pageof 128